Mediastinal staging in non-small-cell lung cancer: Saying goodbye to mediastinoscopy Review
| Authors: | Dunne, E. G.; Fick, C. N.; Jones, D. R. |
| Review Title: | Mediastinal staging in non-small-cell lung cancer: Saying goodbye to mediastinoscopy |
| Abstract: | The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Accurate staging of the mediastinal lymph nodes in resectable non-small-cell lung cancer (NSCLC) is critically important to determine the overall stage of the tumor and guide subsequent management. The staging process typically begins with positron emission tomography (PET) or computed tomography imaging; however, imaging alone is inadequate, and tissue acquisition is required for confirmation of nodal disease. Mediastinoscopy was long considered the gold standard for staging of mediastinal lymph nodes, but, recently, endobronchial ultrasound-guided (EBUS) fine-needle aspiration (FNA) has become the standard of care. EBUS-FNA, in combination with supplementary technologies, such as intranodal forceps biopsy and esophageal ultrasonography, has a high sensitivity and specificity for the diagnosis of nodal metastases. EBUS-FNA is also capable of assessing N1 disease and obtaining adequate tissue for tumor genomic analysis to help guide treatment. In the case of negative findings on EBUS, a confirmatory video mediastinoscopy is still recommended by the European Society of Thoracic Surgeons guidelines. However, whether confirmatory mediastinoscopy is necessary is a matter of debate, and it is not commonly performed in North America. To address this question, Bousema and colleagues performed a randomized noninferiority trial to determine rates of unforeseen nodal metastases after EBUS alone versus EBUS with confirmatory mediastinoscopy in patients with resectable NSCLC. The authors concluded that EBUS alone is noninferior to EBUS with confirmatory mediastinoscopy. These findings affirm our current practice to forgo confirmatory mediastinoscopy after negative findings on EBUS. |
| Keywords: | cancer staging; lymph nodes; neoplasm staging; carcinoma, non-small-cell lung; lung neoplasms; pathology; diagnostic imaging; lung tumor; lymph node; mediastinum; mediastinoscopy; endosonography; non small cell lung cancer; procedures; endoscopic ultrasonography; humans; human |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 22 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-08-01 |
| Start Page: | 3785 |
| End Page: | 3790 |
| Language: | English |
| DOI: | 10.1200/jco.23.00867 |
| PUBMED: | 37267507 |
| PROVIDER: | scopus |
| PMCID: | PMC10419653 |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is David Jones --Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work